^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RGRN-305

    i
    Other names: RGRN-305, CUDC-305, Debio 0932, BEBT-305, MC2-32 HS, MC2-32
    Associations

    News

    Trials
    Company:
    BeBetter Med, Curis, Debiopharm, MC2 Therap, Regranion
    Drug class:
    HSP90 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway. (PubMed, Med Oncol)
    The results revealed that Navitoclax-Debio-0932 combination potently induced intrinsic apoptotic pathway in PC3 cells rather than using drugs alone. The combined treatment of Navitoclax and Debio-0932 displayed synergistic cytotoxic and apoptotic effects on prostate cancer cells, presenting a promising approach for combination therapy in prostate cancer.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CASP7 (Caspase 7) • APAF1 (Apoptotic peptidase activating factor 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    navitoclax (ABT 263) • RGRN-305
    almost3years
    Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines. (PubMed, Mol Biol Rep)
    Debio-0932 decreased the migration of HUVEC cells as compared to the control group. These results indicate that Debio-0932 is a promising compound to treat triple-negative breast cancer and hormone receptor-positive breast cancer, and their metastases.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9)
    |
    HR positive • BCL2 expression • BAX expression
    |
    RGRN-305